BioWorld

Oct. 28, 2002

MedImmune Expects To Take FluMist Back To Panel This Year

An FDA advisory panel later this year is expected to vote on whether FluMist should enter the market as a nasal influenza vaccine for patients who are ages 19 months to 64 years old. (BioWorld Today) Read More

NPS Prices $95.8M Offering From Shelf For Phase III Trials

Rats' Antennae-Like Whiskers Perform Mental Arithmetic, By Neuronal Spectral Mixing

Harvard Bioscience Completes Genomics Solutions Acquisition

Epimmune To Test Public Waters With $9.6M Offering

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 30, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 30, 2026.

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...